TSPO and Alzheimer disease: Translocator protein (TSPO) PET studies in both humans and mice showed two peaks in the AD pathogenesis: an earlier peak associated with neuroprotection, and a later peak that appears when the disease worsens, and is correlated with neurotoxicity (Hamelin et al. 2016; Focke et al. 2019).